Positive Results for 8-week 48 mg Cohort in Phase 1b Trial of DA-1726 On January 5, 2026, MetaVia, Inc. (NASDAQ:MTVA) announced positive and statistically significant results from the 8-week 48 mg ...
DA-1726 48 mg Cohort Study Extended to Eight Weeks On August 6, 2025, MetaVia, Inc. (NASDAQ:MTVA) announced that the company has extended the 48 mg multiple ascending dose (MAD) cohort of the Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results